Vascular calcification in chronic kidney failure: Role of vitamin D receptor

Current Opinion in Investigational Drugs

Volumn 8, Issue 3, 2007, Pages 237-247

  Wu Wong, J Ruth ^a   Melnick, Joel ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Clinical study; Vascular calcification; Vitamin D analog; Vitamin D receptor

Indexed keywords

1,25 DIHYDROXY 22 OXACALCITRIOL; ALFACALCIDOL; ALKALINE PHOSPHATASE; BETA GLUCOSIDASE; CALCIFEDIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; DESMIN; DOXERCALCIFEROL; FETUIN; NICOTINE; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARICALCITOL; PHOSPHORUS; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST;

ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOCRINE EFFECT; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CIRCULATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RECEPTOR BINDING; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INFLAMMATION; MONCKEBERG MEDIAL CALCIFIC SCLEROSIS; MORTALITY; NONHUMAN; OSTEOPOROSIS; PARACRINE SIGNALING; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL; TREATMENT OUTCOME; UREMIA; VITAMIN D DEFICIENCY;

ANIMALS; CALCINOSIS; CALCITRIOL; ERGOCALCIFEROLS; HUMANS; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 33947307775     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 42(4 Suppl 3):S1-201.
2. Summaries for patients. Diagnosis and evaluation of patients with chronic kidney disease: Recommendations from the National Kidney Foundation. Ann Intern Med (2003) 139(2):I36.
3. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet (2000) 356(9224):147-152.
4. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol (2004) 15(5):1307- 1315.
5. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, Owen WF Jr: Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol (2003) 14(9):2373-2380.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 351(13):1296-1305. •• This paper examines the multivariable association between estimated GFR and the risks of death, CV events and hospitalization. An independent, graded association was observed between a reduced estimated GFR and the risk of death, CV events and hospitalization in a large, community-based population.
7. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc (2001) 286(4):421-426.
8. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol (2005) 16(2):507-513.
9. Shemesh J, Apter S, Itzchak Y, Motro M: Coronary calcification compared in patients with acute versus in those with chronic coronary events by using dual-sector spiral CT. Radiology (2003) 226(2):483-488.
10. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol (2003) 14(1):159-168.
11. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol (2004) 8(1):54-58.
12. Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J: Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension (1999) 34(4 Pt 2): 837-842.
13. Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract (2003) 93(4):C124-C130.
14. London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens (2005) 14(6):525-531.
15. Reiss AB, Glass AD: Atherosclerosis: Immune and inflammatory aspects. J Invest Med (2006) 54(3):123-131.
16. London GM: Cardiovascular calcifications in uremic patients: Clinical impact on cardiovascular function. J Am Soc Nephrol (2003) 14(9 Suppl 4):S305-S309.
17. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in endstage renal disease. Hypertension (2001) 38(4):938-942.
18. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P et al: Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 43(3):572-579.
19. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol (2002) 39(4):695-701.
20. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol (2004) 15(12):2959-2964.
21. Nishizawa Y, Jono S, Ishimura E, Shioi A: Hyperphosphatemia and vascular calcification in end-stage renal disease. J Ren Nutr (2005) 15(1):178-182.
22. Ritz E, Gross ML: Hyperphosphatemia in renal failure. Blood Purif (2005) 23(1):6-9.
23. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W: The serum protein α2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem (1996) 271(34):20789-20796.
24. Price PA, Lim JE: The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem (2003) 278(24):22144-22152.
25. Price PA, Nguyen TM, Williamson MK: Biochemical characterization of the serum fetuin-mineral complex. J Biol Chem (2003) 278(24):22153-22160.
26. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim HM, Kitamura Y, Yutani C, Nomura S: Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol (1993) 143(4):1003-1008.
27. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM: Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol (2002) 161(6):2035-2046.
28. 3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll Relat Res (1987) 7(4):305-313.
29. Chang PL, Ridall AL, Prince CW: Calcitriol regulation of osteopontin expression in mouse epidermal cells. Endocrinology (1994) 135(3):863-869.
30. Jono S, Peinado C, Giachelli CM: Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem (2000) 275(26):20197-20203.
31. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature (1997) 390(6655):45-51.
32. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM: Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol (2006) 17(1):262-270.
33. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfα1 in human blood vessels. Kidney Int (2003) 63(3):1003-1011.
34. Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res (2004) 95(6):560-567.
35. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest (2003) 112(3):357-366.
36. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int (2005) 67(3):1070-1077.
37. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res (2000) 87(7):E10-E17.
38. Yang H, Curinga G, Giachelli CM: Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int (2004) 66(6):2293-2299.
39. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH: Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia (1988) 31(1):16-23.
40. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S: Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int (2004) 66(5):2022-2031.
41. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis (2004) 44(6):1024-1030.
42. Qunibi WY, Abouzahr F, Mizani MR, Nolan CR, Arya R, Hunt KJ: Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney Int (2005) 68(1):271-277.
43. Wu-Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, Postl S, Morgan SJ, Reinhart GA: Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther (2006) 318(1):90-98. • This study demonstrated that uremic rats receiving a hyperphosphatemiainducing diet did not exhibit aortic calcification despite elevated levels of serum phosphorus and CaxPi product. In addition, vitamin D analogs failed to induce calcification in primary cultures of human smooth muscle cells, but exhibited differential effects in inducing vascular calcification in vivo.
44. Jones G, Strugnell SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev (1998) 78(4):1193-1231.
45. Andress DL: Vitamin D treatment in chronic kidney disease. Semin Dial (2005) 18(4):315-321.
46. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? Q J Med (2002) 95(12):787-796.
47. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE: Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis (2006) 186(1):20-28.
48. 3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest (1996) 97(7):1577-1588.
49. Rostand SG: Seasonal changes in blood pressure in patients undergoing hemodialysis. N Engl J Med (1999) 340(12):965-966.
50. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int (1999) 56(2):383-392.
51. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation (1998) 98(13):1302-1306. • One of the first papers to show that 1,25-dihydroxyvitamin D3 induces smooth muscle cell calcification in vitro.
52. 3 on inducing smooth muscle cell calcification in vitro cannot be reproduced.
53. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfα1 and downregulation of smooth muscle lineage markers. Circ Res (2001) 89(12):1147- 1154.
54. 3. Cell Tissue Res (1999) 297(2):249-259.
55. 3 suppresses the bone-related Runx2/Cbfα1 gene promoter. Exp Cell Res (2002) 274(2):323-333.
56. Virdi AS, Cook LJ, Oreffo RO, Triffitt JT: Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol (Noisy-le-grand) (1998) 44(8):1237-1246.
57. Rowe PS, Goulding JN, Francis F, Oudet C, Econs MJ, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J et al: The gene for X-linked hypophosphataemic rickets maps to a 200-300kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet (1996) 97(3):345-352.
58. Norman AW: Minireview: Vitamin D receptor: New assignments for an already busy receptor. Endocrinology (2006) 147(12):5542-5548.
59. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol (2005) 289(1):F8-F28.
60. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev (2005) 26(5):662-687.
61. Adorini L: Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol (2002) 2(7):1017- 1028.
62. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, Uskokovic M, Colli E, Maggi M: Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol (2007): doi:10.1016/j.jsbmb.2006.12.065.
63. Niederhoffer N, Bobryshev YV, Lartaud-Idjouadiene I, Giummelly P, Atkinson J: Aortic calcification produced by vitamin D3 plus nicotine. J Vasc Res (1997) 34(5):386-398.
64. Price PA, Williamson MK, Nguyen TM, Than TN: Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem (2004) 279(3):1594-1600.
65. Davies MR, Lund RJ, Hruska KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol (2003) 14(6):1559-1567.
66. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K: Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol (2004) 24(1):25-38.
67. 3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant (2005) 20(7):1370-1377.
68. 3. Nephrol Dial Transplant (2003) 18(9):1770-1776. • This paper reports differential effects of different VDRAs on vascular calcification.
69. 3 is a negative endocrine regulator of the reninangiotensin system. J Clin Invest (2002) 110(2):229-238.
70. Xiang W, Kong J, Chen S, Cao L-P, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC: Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab (2005) 288(1):E125-E132.
71. Wu-Wong JR, Tian J, Nakane M, Ma J, Fey TA, Kroeger P, Fryer RM, Reinhart GA: Cardiovascular disease in chronic kidney failure: The role of VDR activators. Curr Opin Investig Drugs (2006) 7(3):206-213.
72. Goltzman D: Use of genetically modified mice to examine the skeletal anabolic activity of vitamin D. J Steroid Biochem Mol Biol (2006):doi:10.1016/j.jsbmb.2006.12.087.
73. 3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1α-hydroxylase and parathyroid hormone null alleles. Endocrinology (2006) 147(10):4801-4810.
74. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D: Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem (2004) 279(16):16754-16766.
75. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D: Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA (2001) 98(13):7498-7503.
76. 3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation (1997) 96(5):1477-1481.
77. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation (1997) 96(6):1755-1760.
78. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in endstage renal disease. J Am Soc Nephrol (2004) 15(7):1943-1951.
79. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW: Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif Tissue Int (2001) 68(5):271-276.
80. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC: Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler Thromb Vasc Biol (2000) 20(8):1926-1931.
81. Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G, Ragi-Eis S, Chandler J: The prevalence of vitamin D inadequacy amongst women with osteoporosis: An international epidemiological investigation. J Intern Med (2006) 260(3):245-254.
82. Scharla S: Relative value of plain vitamin D and of biologically active vitamin D in the prevention and treatment of osteoporosis. Z Rheumatol (2006) 65(5):391-394, 396-399.
83. Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T, Yamazaki C, Sakai R, Ohmori H, Morita O, Iseki K et al: An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial (2004) 8(1):3-32.84.
84. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 349(5):446-456. • Data from retrospective clinical studies are described which show that the survival benefit of patients undergoing hemodialysis is in the order of paricalcitol > calcitriol.
85. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol (2005) 16(4):1115- 1125. • Data from retrospective clinical studies show that the survival benefit of hemodialysis is in the order of VDR therapy > no VDR therapy.
86. 3 users in a haemodialysis population. Nephrol Dial Transplant (2004) 19(1):179-184.
87. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int (2006) 70(4):771-780. • This study examined associations between survival and quarterly laboratory values, and administered paricalcitol in a 2-year (July 2001 to June 2003) cohort of 58,058 maintenance hemodialysis patients, all from DaVita dialysis clinics in the US using both time-dependent cyclooxygenase (COX) models with repeated measures and fixed-covariate COX models with only baseline values. The results indicated that administration of any dose of paricalcitol was associated with improved survival in time-varying models.
88. Young EW, Albert JM, Akiba T, Greenwood R, Kimata N, Levin NW, Piera L, Saran R: Vitamin D therapy and mortality in the dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol (2005) 16:TH-PO0735. • Data from the DOPPS time-dependent analyses are presented which show that the dialysis survival benefit is in the order of intravenous paricalcitol > intravenous calcitriol > oral VDRAs = no VDRAs.
89. 3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation (2005) 111(13):1666-1671.
90. 3 by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol (2002) 13(3):621-629.
91. 3-1α- hydroxylase. J Clin Endocrinol Metab (2001) 86(2):888-894.
92. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE: VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem (2006):doi:10.1002/jcb.21133.
93. Thornell L, Carlsson L, Li Z, Mericskay M, Paulin D: Null mutation in the desmin gene gives rise to a cardiomyopathy. J Mol Cell Cardiol (1997) 29(8):2107-2124.
94. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature (1997) 386(6620):78-81.
95. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 12(9):1260-1268.
96. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest (1998) 101(7):1468-1478.
97. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM: Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: Evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med (2002) 196(8):1047-1055.
98. 3, intact PTH and GFR in CKD patients.